Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

This study has been completed.

Sponsor:

Collaborators:

Gilead Sciences

Merck

Information provided by (Responsible Party):

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

ClinicalTrials.gov Identifier:

NCT00822315

First received: January 13, 2009

Last updated: January 17, 2013

Last verified: January 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	June 2012
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)